Download MendeleyA novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.
Matsui, Y., Yasumatsu, I., Yoshida, K.I., Iimura, S., Ikeno, Y., Nawano, T., Fukano, H., Ubukata, O., Hanzawa, H., Tanzawa, F., Isoyama, T.(2018) Acta Crystallogr F Struct Biol Commun 74: 156-160
- PubMed: 29497019
- DOI: https://doi.org/10.1107/S2053230X18002108
- Primary Citation of Related Structures:
5WVD - PubMed Abstract:
Mitogen-activated protein kinase (MAPK)-interacting kinases 1 (Mnk1) and 2 (Mnk2) modulate translation initiation through the phosphorylation of eukaryotic translation initiation factor 4E, which promotes tumorigenesis. However, Mnk1 and Mnk2 are dispensable in normal cells, suggesting that the inhibition of Mnk1 and Mnk2 could be effective in cancer therapy. To provide a structural basis for Mnk1 inhibition, a novel Mnk1 inhibitor was discovered and the crystal structure of Mnk1 in complex with this inhibitor was determined. The crystal structure revealed that the inhibitor binds to the autoinhibited state of Mnk1, stabilizing the Mnk-specific DFD motif in the DFD-out conformation, thus preventing Mnk1 from switching to the active conformation and thereby inhibiting the kinase activity. These results provide a valuable platform for the structure-guided design of Mnk1 inhibitors.
Organizational Affiliation:
Daiichi Sankyo RD Novare Co. Ltd, 1-16-13 Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan.
